Lv1
70 积分 2023-05-26 加入
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
3个月前
已完结
Immune disguise: the mechanisms of Neu5Gc inducing autoimmune and transplant rejection
5个月前
已完结
Basic Regulatory Science Behind Drug Substance and Drug Product Specifications of Monoclonal Antibodies and Other Protein Therapeutics
6个月前
已完结
Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes
6个月前
已完结
Abstract 1781: HPN536, a T cell-engaging, mesothelin/CD3-specific TriTAC for the treatment of solid tumors
8个月前
已关闭
Cadonilimab: First Approval
9个月前
已完结
CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia
10个月前
已完结
CRISPR/Cas9-based gene-editing technology for sickle cell disease
10个月前
已完结
Is CRISPR safe? Genome editing gets its first FDA scrutiny
11个月前
已完结
CRISPR-Mediated Genome Engineering in Cell Lines
1年前
已关闭
皖公网安备34019202002308
